Alumis Inc. (ALMS) - Cash per Share

Alumis Pharma - graphic logo of issuer ALMS

Alumis Inc. (ALMS) went public to secure the capital necessary to finalize the development of oral immunotherapies. The estimated cash per share confirms financial stability, where the 3.29 metric determines the liquidity parameter status. The business focuses on selective TYK2 inhibitors for targeted therapy, while the high scalability of potential blockbuster formulas enables aggressive expansion into global markets.

ALMS - Alumis Cash per Single Share over the range 06/29/2024 - 11/20/2026

Comprehensive metric breakdowns and analytics for Alumis Inc (ALMS)

- market price and analyst price targets:
- cash availability and cash flow indicators:
Comprehensive company analysis:Alumis Inc.
Signature product of Alumis

This metric reflects the operational resilience of the business by measuring the volume of liquid assets available to cover liabilities without selling fixed assets. For Alumis Inc. (ALMS), which finances costly immunological research and retains scientists through stock options, the cash per share serves as an indicator of capital headroom, allowing investors to promptly identify the risk of asset value degradation relative to its cash reserves.